Radient Pharmaceuticals Corporation (RPC) /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 0.43, -0.04, -9.04%) announced today broad availability of its 2010 Onko-Sure(R) Reference Guide for the Company's USFDA-approved Onko-Sure(R) in vitro diagnostic (IVD) cancer test kit.
The 2010 Onko-Sure(R) Reference Guide is a commercially published compilation of Radient Pharmaceuticals general information and clinical studies on the Company's Onko-Sure(R) IVD cancer test kit. Designed to provide oncologists, physicians and clinicians with the most current and important information for Onko-Sure(R), the guide also serves as a comprehensive reference for other health care professionals, consumers and patients.
In addition to general Company information and Onko-Sure(R) clinical study data, RPC's 2010 Onko-Sure(R) Reference Guide provides a comprehensive list of key references, resources and other published materials users can consult to better understand the medical utilities of Onko-Sure(R), how healthcare providers and patients can use the test and the science behind Onko-Sure(R).
RPC's Onko-Sure(R) IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure(R) is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment